default author photo

Qing Li

Tianjin Medical University - National Clinical Research Center for Cancer

Tianjin, 300060

China

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC)

  • Tianjin Medical University - National Clinical Research Center for Cancer

SCHOLARLY PAPERS

2

DOWNLOADS

50

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

The Different Sequences of Cdk4/6 Inhibitor and Mtor Inhibitor in Hr+/Her2- Advanced Breast Cancer: A Multicenter Real-World Study

Number of pages: 19 Posted: 22 Jul 2024
Yuqian Liao, Yujing Tan, Yipeng Li, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Qiao Li, Yang Luo, Bo Lan, Shanshan chen, Binghe Xu, Hanfang Jiang, Weihong Zhao and Ying Fan
Jiangxi Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Chinese Academy of Medical Sciences - Department of Medical Oncology, Beijing University, Government of the People's Republic of China - Chinese PLA General Hospital and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC)
Downloads 30 (1,318,317)

Abstract:

Loading...

therapeutic sequence, CDK4/6 inhibitor, everolimus, survival outcome

2.

Safety and Efficacy Study of Oral Metronomic Capecitabine Combined with Pyrotinib in Her2-Positive Metastatic Breast Cancer: A Phase Ii Trial

Number of pages: 10 Posted: 22 Jun 2023
Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li and Binghe Xu
Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of VIP Medical Services, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer and Chinese Academy of Sciences (CAS)
Downloads 20 (1,448,301)

Abstract:

Loading...

Phase II study, metastatic breast cancer, HER2-positive, pyrotinib, capecitabine, metronomic chemotherapy